<DOC>
	<DOC>NCT00810147</DOC>
	<brief_summary>The purpose of this study is to determine the safety and tolerability of BMS-708163 in patients with mild to moderate Alzheimer's disease over a treatment period of 12-weeks and the course of any potential effects during a 12-week wash-out period</brief_summary>
	<brief_title>A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Clinical diagnosis of Mild to Moderate Alzheimer's disease (MMSE 1626) 6 Month cognitive decline Stable marketed AD therapy x2 months or additional marketed AD therapy during study Score of &lt;=4 on the Modified Hachinski Ischemia Scale CT results consistent with Alzheimer's disease Medically stable 6 years education Reliable study partner (caregiver) Must be able to swallow capsules Premenopausal women Dementia due to other causes than Alzheimer's disease History of stroke Immunocompromised Active peptic ulcer, GI bleed, chronic inflammatory bowel disease, chronic diarrhea or past GI surgery that would impact drug absorption Unstable Vitamin B12 deficiency Hematologic or solid malignancy within 5 years Geriatric Depression Scale &gt;= 6 Unstable medical condition Alcohol or drug abuse history with 12months of study entry Significant drug allergy Alzheimer's disease modification experimental therapy with 12 months of study entry Prisoners, compulsory psychiatric patients, or residents of nursing home or skilled nursing facility at entry Any other experimental therapy with 30days of study entry</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>